Chemokine Therapeutics is a product-focused biotechnology company developing drugs that harness the therapeutic potential of stem cells through chemokine pathways.
Chemokines are a new class of cytokines, proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation and maturation of cells necessary for fighting infection, as well as tissue repair and regeneration.
Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation.
Chemokine Therapeutics is a leader in research in this field. The Company has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth.
| Chemokine Therapeutics Closes $885,000 Offering | 06/16/2008 - 07:00 | $0Million |
| Chemokine Therapeutics Closes $1,050,000 Offering | 02/08/2008 - 08:00 | $1Million |
| Chemokine Therapeutics Closes Additional $1.06 million Private Placement | 03/23/2006 - 08:00 | $1Million |
| Chemokine Therapeutics Closes $5.8 million Private Placement | 03/22/2006 - 08:00 | $5Million |